ESMO 2018 News - Episode 8
Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses data presented on lung cancer during the 2018 ESMO Congress.
In a paired sample analysis of the phase III FLAURA trial, investigators sought to determine markers of acquired resistance to frontline osimertinib (Tagrisso) in EGFR-mutant non—small cell lung cancer (NSCLC). Preliminary data showed that MET amplification and EGFR C797S mutations are the most commonly observed alterations associated with resistance to first-line osimertinib in this patient population.
Phase II trial findings showed that the combination of tepotinib plus gefitinib (Iressa) improved progression-free survival and overall response versus chemotherapy in patients with MET-mutated EGFR-positive NSCLC resistant to prior EGFR TKI therapy. This was the first randomized study to compare tepotinib and gefitinib with chemotherapy in relapsed patients with EGFR-mutated NSCLC whose tumors have MET overexpression or amplification.
Additionally, immunotherapy remains a big area in both NSCLC and small cell lung cancer, and Ramalingam says that its role is still being understood.